Europe’s Innovative Medicines Initiative (IMI) has launched a multi-million euro funding call to accelerate solutions to the deadly coronavirus (COVID-19). Part of the wider EU response to COVID-19, IMI’s competitive funding call is open to innovators, SMEs and universities with proposals to rapidly develop treatments and diagnostic tests.
“Collaborative projects involving companies, universities and public bodies have the potential to dramatically accelerate the development of new treatments and diagnostics to tackle this threat to global public health,” said Dr Pierre Meulien, IMI Executive Director. “During the outbreak of Ebola in western Africa, we demonstrated that IMI can rapidly launch projects and deliver results in an outbreak setting, and I am confident that we can do it again for the coronavirus.”
More than 6,500 deaths have been caused by COVID-19 so far, with the epidemic continuing to spread worldwide. To help find answers to a worsening global crisis, IMI has dedicated a budget of €45M to the funding call, which will rise to €90 with ‘in-kind’ backing by its pharma sector partners.
“I welcome the rapid response of IMI to the coronavirus outbreak. This collaboration between the public and the private sectors brings their expertise and resources together in our fight against the coronavirus outbreak. This will help speed up the development of treatments and diagnostics in face of this global emergency and increase our preparedness for future outbreaks,” added Mariya Gabriel, Commissioner for Innovation, Research, Culture, Education and Youth.
The deadline for submitting proposals is 31 March 2020.